Lym-1 and lym-2 targeted car cell immunotherapy

Abstract

CAR cells targeting and antibodies human HLA-DR are described as a new method of cancer treatment. It is proposed that HLA-DR CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-DR.

1 .- 51 . (canceled) 
     
     
         52 . An isolated anti-Lym-2 antibody or an antigen binding fragment thereof comprising a heavy chain variable region comprising complementarity-determining regions (CDRs) comprising SEQ ID NOs: 2, 4, and 6; and a light chain variable region comprising CDRs comprising SEQ ID NOs: 12, 14, and 16. 
     
     
         53 . The isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52 , wherein the heavy chain variable region comprises a polypeptide comprising at least 90% sequence identity to SEQ ID NO: 10 and comprising the CDRs comprising of SEQ ID NOs: 2, 4, 6, 12, 14 and 16. 
     
     
         54 . The isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52 , wherein the heavy chain variable region comprises SEQ ID NO: 10. 
     
     
         55 . The isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52 , wherein the light chain variable region comprises a polypeptide comprising at least 90% sequence identity to SEQ ID NO: 20 and comprising the CDRs comprising of SEQ ID NOs: 2, 4, 6, 12, 14 and 16. 
     
     
         56 . The isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52 , wherein the light chain variable region comprises SEQ ID NO: 20. 
     
     
         57 . The isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52 , wherein the fragment of the isolated anti-Lym-2 antibody is a scFv. 
     
     
         58 . The isolated anti-Lym-2 antibody of  claim 52 , wherein the isolated anti-Lym-2 antibody is a monoclonal antibody. 
     
     
         59 . An isolated nucleic acid sequence encoding the isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52  or its complement or an equivalent of each thereof. 
     
     
         60 . A vector comprising the isolated nucleic acid sequence of  claim 59 . 
     
     
         61 . An isolated cell comprising the isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52 . 
     
     
         62 . A complex comprising the isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52  bound to a cell expressing HLA-DR. 
     
     
         63 . A method of inhibiting the growth of a tumor or treating a cancer that overexpresses HLA-DR as compared to a normal, non-cancerous counterpart cell in a subject in need thereof, comprising administering to the subject an effective amount of the isolated anti-Lym-2 antibody or the antigen binding fragment thereof of  claim 52 . 
     
     
         64 . The method of  claim 63 , further comprising administering to the subject an anti-tumor therapy other than an HLA-DR CAR therapy. 
     
     
         65 . The method of  claim 63 , wherein the tumor is cancerous. 
     
     
         66 . The method of  claim 63 , wherein the cancer is a B-cell lymphoma or a leukemia. 
     
     
         67 . The method of  claim 63 , wherein the subject is a mammal.